
    
      A single-center, prospective, randomized, open label, parallel study to compare the efficacy
      and safety of raltegravir-based versus efavirenz-based plus optimal nucleoside
      reverse-transcriptase inhibitors(NRTIs) backbone combination therapy in treatment-na√Øve
      patients with HIV-1 infection.
    
  